Buy Drostanolone Enanthate 200 (Masteron) – HilmaBioCare EU
Product Overview & Pharmaceutical Specifications
Drostanolone Enanthate 200 is described in the supplied product information as an injectable, oil-based sterile solution containing drostanolone enanthate as its active pharmaceutical ingredient.
Product Specifications
- Product name: Drostanolone Enanthate 200
- Alternative name supplied: Masteron
- Active pharmaceutical ingredient (API): Drostanolone enanthate
- Strength: 200 mg/ml
- Dosage form: Injectable, oil-based sterile solution
- Route of administration: Injection
- Pack size: 10 ml
- Packaging: Multiple-dose vial
- CAS number supplied: 472-61-145
- Molecular formula: C27H44O3
- Molecular mass: 416.64 g/mol
- Manufacturer/company: Hilma Biocare
- Market status supplied: Prescription
- Storage: Store in a cool, dry place between 15–25°C. Protect from light.
Pharmaceutical Formulation
The supplied product description identifies drostanolone enanthate as a synthetic derivative of dihydrotestosterone (DHT).
The source describes drostanolone as having anabolic and androgenic properties and states that it does not aromatize to estrogen. It also describes a combination of short-acting propionate and long-acting enanthate ester characteristics, with rapid increases in serum drostanolone levels and a stated sustained duration of approximately 5–8 days.
The stated formulation contains drostanolone enanthate as its active ingredient. No propionate ester has been added to the product specifications because it is not listed as an active ingredient in the supplied composition.
Pharmacology & Product Information
Pharmacological Class
Drostanolone is described in the supplied documentation as an anabolic steroid and synthetic derivative of dihydrotestosterone.
Anabolic steroids are synthetic derivatives of testosterone. The supplied clinical pharmacology information states that these compounds can demonstrate both anabolic and androgenic properties and that complete separation of these effects has not been achieved.
Mechanism of Action
The supplied information states that drostanolone attaches to androgen receptors and is associated with increased nitrogen retention and protein synthesis.
The source also describes activity through DHT-modulated pathways and characterizes drostanolone as an estrogen antagonist. It states that drostanolone does not aromatize to estrogen.
Endocrine Effects
According to the supplied clinical pharmacology information, anabolic steroids can suppress gonadotropic pituitary function.
During exogenous administration of anabolic androgens, endogenous testosterone release may be inhibited through suppression of pituitary luteinizing hormone (LH). At larger doses, spermatogenesis may be suppressed through feedback inhibition of pituitary follicle-stimulating hormone (FSH).
The supplied information also identifies inhibition of gonadotropin secretion as a potential metabolic/endocrine effect.
Pharmacokinetic Information
The supplied source states that drostanolone undergoes hepatic metabolism and reports a half-life of 2–3 days after separation of the ester.
The product description also states that the enanthate formulation produces sustained serum drostanolone levels for approximately 5–8 days.
No additional pharmacokinetic parameters, such as clearance or volume of distribution, are supplied.
Documented Applications in Supplied Product Information
The supplied source lists the following applications:
- Restoration of muscle tissue described as atrophied during recovery from traumatic injury
- Addressing muscle catabolism in patients with a wasting syndrome
- Treatment of certain types of anaemia described as non-responsive to first-line agents
- Use as an estrogen antagonist in treatment of breast cancer
These applications are reproduced from the supplied product information and have not been independently verified against current EU clinical guidelines or marketing authorizations.
Contraindications
The supplied product information lists the following contraindications and populations for whom the product is not indicated:
- Women
- Children
- Elderly patients
- Women who are pregnant or may become pregnant because of possible fetal masculinization
- Patients with nephrosis
- Patients in the nephrotic phase of nephritis
- Patients with hypercalcaemia
- Patients with testicular cancer
- Patients with prostate cancer
- Patients with breast cancer
- Patients with liver damage
- Patients with kidney damage
- Patients with a history of stroke
- Patients with high blood pressure
- Patients with heart disease
- Patients with respiratory problems
Precautions
The supplied documentation reports that elevated liver enzymes and, in rare cases, hepatic dysfunction may occur.
It recommends periodic monitoring of liver function, including:
- Serum bilirubin
- AST
- ALT
- AP
The source also states that oedema may increase in patients receiving concurrent adrenal cortical steroid or ACTH therapy.
Anabolic steroid hormones may increase low-density lipoproteins (LDL) and decrease high-density lipoproteins (HDL). The supplied source states that lipid levels generally return toward normal following discontinuation of treatment.
The documentation further states that anabolic steroids may reduce clotting factors II, V, VII and X and may increase prothrombin time (PT).
Patients are instructed in the supplied source to report warfarin use and any irregular bleeding.
Adverse Reactions & Safety Information
The supplied product documentation reports the following adverse reactions and potential effects.
Male Reproductive Effects
- Gynecomastia
- Excessive frequency and duration of penile erections
- Oligospermia
Skin & Appendages
- Hirsutism
- Male-pattern baldness
- Acne
- Gynecomastia
Fluid & Electrolyte Disturbances
- Retention of sodium
- Retention of chloride
- Retention of water
- Retention of potassium
- Retention of calcium
- Retention of inorganic phosphates
Gastrointestinal & Hepatic Effects
- Nausea
- Cholestatic jaundice
- Alterations in liver function tests
- Rarely, hepatocellular neoplasms
- Peliosis hepatitis
- Hepatic adenomas
- Cholestatic hepatitis
Hematologic Effects
- Suppression of clotting factors II, V, VII and X
- Potential bleeding in patients receiving anticoagulant therapy
Nervous System Effects
- Changes in libido
- Aggression
- Headache
- Anxiety
- Depression
- Generalized paresthesia
Metabolic Effects
- Reduced glucose tolerance
- Increased creatinine clearance
- Inhibition of gonadotropin secretion
Other Reported Effects
- Serum lipid changes
- Hypercalcaemia
- Hypertension
- Oedema
- Priapism
- Potentiation of sleep apnea
Patient Monitoring
The supplied product information recommends monitoring of:
- Serum cholesterol
- HDL
- LDL
- Triglycerides (TG)
- Haemoglobin
- Haematocrit
- Hepatic function tests, including AST and ALT
- Prostate-specific antigen (PSA)
- Total testosterone
- Free testosterone
- Bioavailable testosterone
- Dihydrotestosterone (DHT)
- Estradiol
The source states that male patients over 40 should undergo a digital rectal examination and PSA evaluation before androgen use.
Periodic prostate evaluations should continue during androgen therapy, particularly in patients experiencing difficulty with urination or changes in voiding habits.
Dosage & Administration
The supplied product information states:
Adult male: 100–150 mg injected intramuscularly every 3–5 days for a duration of 4–8 weeks.
This dosage information is reproduced from the supplied source and should not be interpreted as individualized medical advice. Administration of an injectable prescription product should follow the applicable official prescribing information and the instructions of a qualified healthcare professional.
Presentation & Storage
Presentation: Drostanolone Enanthate 200 mg/ml, 10 ml multiple-dose vial.
Storage: Store in a cool, dry place between 15–25°C. Protect from light.
Scientific & Regulatory References
No PubMed references, DOI references, clinical-literature citations, manufacturer documents or official regulatory-source links were supplied with the product data.
Accordingly, no external scientific or regulatory references have been added.
The supplied source identifies the market status as Prescription. No specific EU Member State marketing authorization, EU-wide authorization, national authorization number or regulatory approval status was supplied. Therefore, no EU-wide authorization claim is made here.
Pharmaceutical Terms & Compliance
Important: This product information is provided for informational purposes only and does not replace professional medical advice. Always consult a qualified healthcare professional and follow the official product information, prescribing instructions and applicable regulations in your country.
Drostanolone Enanthate 200 is identified in the supplied source as a prescription product. Regulatory requirements, authorization status, dispensing conditions and legal availability may differ between European countries. No claim of EU-wide marketing authorization or approval is made based solely on the supplied product information.
